ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.
The titles for the accepted abstracts are provided below and accessible online at: https://www.asn-online.org/education/kidneyweek/2025/program-search-abstract.aspx
Late-Breaking Poster Presentation
Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)
Session Title: Late-Breaking Science Posters [LB-PO]
Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO1203
Other Poster Presentation
Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel
Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]
Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO0575
Following the event, a copy of the poster presentations will be available on the Company’s website at: https://prokidney.com/our-technology/publications/
Additional information on ASN Kidney Week 2025 can be accessed online at:
https://www.asn-online.org/education/kidneyweek
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com
Media Contact
Audra Friis
audrafriis@sambrown.com
Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
